Immunotherapy and urothelial carcinoma: An overview and future prospectives
F Pierantoni, M Maruzzo, M Gardi, E Bezzon… - Critical Reviews in …, 2019 - Elsevier
Background Urothelial carcinoma (UC) is a common malignancy with a high mortality rate
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …
Immunotherapy and urothelial carcinoma: An overview and future prospectives.
F Pierantoni, M Maruzzo, M Gardi… - Critical Reviews in …, 2019 - europepmc.org
Background Urothelial carcinoma (UC) is a common malignancy with a high mortality rate
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …
[PDF][PDF] Immunotherapy and urothelial carcinoma: An overview and future prospectives
F Pierantonia, M Maruzzoa, M Gardib… - Critical Reviews in …, 2019 - academia.edu
Background: Urothelial carcinoma (UC) is a common malignancy with a high mortality rate
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …
Immunotherapy and urothelial carcinoma: An overview and future prospectives
F Pierantoni, M Maruzzo, M Gardi… - Critical reviews in …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Urothelial carcinoma (UC) is a common malignancy with a high mortality rate
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …